Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor

R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

Sylvia Braselmann, Vanessa Taylor, H. Zhao et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 511 citations

Life Sciences, Immunology, Pharmacology +17

A Crucial Role for the p110δ Subunit of Phosphatidylinositol 3-Kinase in B Cell Development and Activation

Elizabeth Clayton, Giuseppe Bardi, Sarah E. Bell et al. · The Journal of Experimental Medicine · 2002 · 441 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials

James B. Bussel, Donald M. Arnold, Elliot Grossbard et al. · American Journal of Hematology · 2018 · 351 citations · Full text

Medicine, Hematology, Pharmacology +11

Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve‐week, randomized, placebo‐controlled trial

Michael E. Weinblatt, Arthur Kavanaugh, Rubén Burgos‐Vargas et al. · Arthritis & Rheumatism · 2008 · 336 citations

Medicine, Immunology, Pharmacology +12

Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils

Alison M. Condliffe · Blood · 2005 · 292 citations · Full text

Life Sciences, Immunology, Physiology +13